Celgene Loses Sanctions Bid Against Teva Unit In Patent Row
By Carolina Bolado ( May 8, 2013, 9:10 PM EDT) -- A Florida federal judge on Wednesday denied Celgene Corp.'s bid to sanction a Teva Pharmaceutical Industries Ltd. unit for pursuing a patent infringement case involving Celgene's bone-marrow cancer drug Vidaza that Celgene calls "frivolous from the outset."...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.